Literature DB >> 27209205

Mouse models for radiation-induced cancers.

Leena Rivina1, Michael J Davoren2, Robert H Schiestl.   

Abstract

Potential ionising radiation exposure scenarios are varied, but all bring risks beyond the simple issues of short-term survival. Whether accidentally exposed to a single, whole-body dose in an act of terrorism or purposefully exposed to fractionated doses as part of a therapeutic regimen, radiation exposure carries the consequence of elevated cancer risk. The long-term impact of both intentional and unintentional exposure could potentially be mitigated by treatments specifically developed to limit the mutations and precancerous replication that ensue in the wake of irradiation The development of such agents would undoubtedly require a substantial degree of in vitro testing, but in order to accurately recapitulate the complex process of radiation-induced carcinogenesis, well-understood animal models are necessary. Inbred strains of the laboratory mouse, Mus musculus, present the most logical choice due to the high number of molecular and physiological similarities they share with humans. Their small size, high rate of breeding and fully sequenced genome further increase its value for use in cancer research. This chapter will review relevant m. musculus inbred and F1 hybrid animals of radiation-induced myeloid leukemia, thymic lymphoma, breast and lung cancers. Method of cancer induction and associated molecular pathologies will also be described for each model.
© The Author 2016. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 27209205      PMCID: PMC6280996          DOI: 10.1093/mutage/gew019

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  278 in total

1.  Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.

Authors:  C H Hensel; R H Xiang; A Y Sakaguchi; S L Naylor
Journal:  Oncogene       Date:  1991-06       Impact factor: 9.867

2.  Late effects of treatment for childhood Hodgkin's disease.

Authors:  L B Travis; R E Curtis; J D Boice
Journal:  N Engl J Med       Date:  1996-08-01       Impact factor: 91.245

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture.

Authors:  Rita A Busuttil; Miguel Rubio; Martijn E T Dollé; Judith Campisi; Jan Vijg
Journal:  Aging Cell       Date:  2003-12       Impact factor: 9.304

5.  Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology.

Authors:  R Sankila; S Garwicz; J H Olsen; H Döllner; H Hertz; A Kreuger; F Langmark; M Lanning; T Möller; H Tulinius
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

Review 6.  Acute nonlymphocytic leukemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases.

Authors:  E C Cadman; R L Capizzi; J R Bertino
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860

7.  PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain.

Authors:  Wendy D Cook; Benjamin J McCaw; Christopher Herring; Deborah L John; Simon J Foote; Stephen L Nutt; Jerry M Adams
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

8.  Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

Authors:  B J Alexander; J E Rasko; G Morahan; W D Cook
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

9.  Relationship of leukemia risk to radiation dose following cancer of the uterine corpus.

Authors:  R E Curtis; J D Boice; M Stovall; L Bernstein; E Holowaty; S Karjalainen; F Langmark; P C Nasca; A G Schwartz; M J Schymura
Journal:  J Natl Cancer Inst       Date:  1994-09-07       Impact factor: 13.506

10.  Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians.

Authors:  John D Mathews; Anna V Forsythe; Zoe Brady; Martin W Butler; Stacy K Goergen; Graham B Byrnes; Graham G Giles; Anthony B Wallace; Philip R Anderson; Tenniel A Guiver; Paul McGale; Timothy M Cain; James G Dowty; Adrian C Bickerstaffe; Sarah C Darby
Journal:  BMJ       Date:  2013-05-21
View more
  9 in total

1.  Recombinant cell-detecting RaDR-GFP in mice reveals an association between genomic instability and radiation-induced-thymic lymphoma.

Authors:  Akira Fujimori; Hirokazu Hirakawa; Cuihua Liu; Taishin Akiyama; Bevin P Engelward; Jac A Nickoloff; Masao Suzuki; Bing Wang; Mitsuru Nenoi; Sei Sai
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

2.  Differences in the Establishment of Gut Microbiota and Metabolome Characteristics Between Balb/c and C57BL/6J Mice After Proton Irradiation.

Authors:  Yuchen Li; Li Sui; Hongling Zhao; Wen Zhang; Lei Gao; Weixiang Hu; Man Song; Xiaochang Liu; Fuquan Kong; Yihao Gong; Qiaojuan Wang; Hua Guan; Pingkun Zhou
Journal:  Front Microbiol       Date:  2022-05-06       Impact factor: 6.064

Review 3.  Are Exposures to Multiple Frequencies the Key to Future Radiofrequency Research?

Authors:  Zenon Sienkiewicz; Carolina Calderón; Kerry A Broom; Darren Addison; Amélie Gavard; Louise Lundberg; Myron Maslanyj
Journal:  Front Public Health       Date:  2017-12-08

Review 4.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

Review 5.  Magnetic Resonance Imaging for Translational Research in Oncology.

Authors:  Maria Felicia Fiordelisi; Carlo Cavaliere; Luigi Auletta; Luca Basso; Marco Salvatore
Journal:  J Clin Med       Date:  2019-11-06       Impact factor: 4.241

6.  Total body irradiation causes a chronic decrease in antioxidant levels.

Authors:  Lue Sun; Yohei Inaba; Yu Sogo; Atsuo Ito; Mahesh Bekal; Koichi Chida; Takashi Moritake
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

7.  Transcriptomes of Wet Skin Biopsies Predict Outcomes after Ionizing Radiation Exposure with Potential Dosimetric Applications in a Mouse Model.

Authors:  Abdulnaser Alkhalil; John Clifford; Stacyann M Miller; Aarti Gautam; Marti Jett; Rasha Hammamieh; Lauren T Moffatt; Jeffrey W Shupp
Journal:  Curr Issues Mol Biol       Date:  2022-08-18       Impact factor: 2.976

8.  Analyses of cancer incidence and other morbidities in gamma irradiated B6CF1 mice.

Authors:  Alia Zander; Tatjana Paunesku; Gayle E Woloschak
Journal:  PLoS One       Date:  2020-08-20       Impact factor: 3.240

Review 9.  Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.

Authors:  Jessica S Helm; Ruthann A Rudel
Journal:  Arch Toxicol       Date:  2020-05-13       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.